Results 141 to 150 of about 18,037 (235)

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, Volume 89, Issue 6, Page 1011-1019, December 2026.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

Journal of Internal Medicine, Volume 300, Issue 6, Page 758-778, December 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. [PDF]

J Clin Med, 2023
Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A.   +5 more
europepmc   +1 more source

Primary Systemic Carnitine Deficiency Complicated With Severe Cardiomyopathy: A Case Report

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT We report a 6‐year‐2‐month‐old girl with SLC22A5‐related PSCD presenting with severe cardiomyopathy, pneumonia, and anemia. Trio‐WES confirmed the c.338G>A homozygous variant. L‐carnitine replacement, combined with standard heart‐failure therapy, was followed by prominent cardiac recovery, alerting clinicians to suspect PSCD in unexplained ...
Xiaojuan Luo, Jia Luo
wiley   +1 more source

Sodium-Glucose Co-Transporter 2 Inhibitors and Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors During Mineralocorticoid Receptor Antagonist Therapy: A Real-World Cohort Study. [PDF]

Pharmacy (Basel)
Almalki AH, Alorainan NA, Bukhari MA, Dokhaikh FA, Quqandi SMA, Merdad RH, Sadagah LF.   +6 more
europepmc   +1 more source

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review. [PDF]

Int J Mol Sci, 2022
Mai X, Kometani M, Yoneda T.
europepmc   +1 more source

Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort

Clinical Cardiology, Volume 49, Issue 11, November 2026.
In 49 high‐risk ambulatory heart failure patients with persistent congestion despite oral diuretics, subcutaneous furosemide was well tolerated, with a 20.4% 30‐day HF hospitalization rate. Among non‐hospitalized patients, the median NYHA class improved from III to II, and the weight decreased by 2.6 kg.
Omar Jafar, Ann Harper, Angela Toepp, Amin Yehya   +3 more
wiley   +1 more source

The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice. [PDF]

Cardiovasc Diabetol
Monmirel-Fauconnier M, Pieronne-Deperrois M, Bonnard B, Frimat C, Linghui K, Ni Dheasmhunaigh A, Nicol L, Morchid S, Renet S, Dumesnil A, Richard V, Fève B, Jaisser F, Boulkroun S, Mulder P, Ouvrard-Pascaud A.   +15 more
europepmc   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs. [PDF]

J Vet Intern Med
Ward JL, Goodman J, Blondel T, Zdyrski C, Manson E, Merodio M, Lamers RP, Allenspach K, Guillot E, Mochel JP.   +9 more
europepmc   +1 more source